328289-91-4

Usage

Uses

Used in Pharmaceutical Industry:
4-(2,6-Dimethyl-piperidin-1-ylmethyl)-phenylamine is used as a chemical intermediate for the synthesis of various pharmaceuticals and organic compounds. Its unique structure with a piperidine ring and phenyl group contributes to the development of new drugs with potential therapeutic applications.
Used in Medicinal Chemistry Research:
4-(2,6-Dimethyl-piperidin-1-ylmethyl)-phenylamine is used as a research compound in medicinal chemistry for exploring its potential as an anticancer and antiviral agent. Its biological activity, attributed to the presence of the piperidine ring, is of interest to scientists working on drug discovery and development.
Used in Drug Synthesis:
4-(2,6-Dimethyl-piperidin-1-ylmethyl)-phenylamine is used as a key component in the synthesis of drugs with potential therapeutic benefits. Its versatile structure allows for the creation of various drug candidates that can be further optimized for improved efficacy and safety.

Relevant academic research and scientific papers

BETA-KETOAMIDE COMPOUNDS HAVING AN MCH-ANTAGONISTIC EFFECT AND MEDICAMENTS CONTAINING SAID COMPOUNDS

The invention relates to β-ketoamide compounds of general formula (I) wherein the groups and radicals A, B, b, X, Y, Z, R1, R2, R3, R5a and R5b have the designations cited in patent claim 1. The invention also relates to medicaments containing at least one inventive amide. As a result of the MCH receptor antagonistic activity, the inventive medicaments are suitable for treating metabolic disorders and/or eating disorders, especially adipositas, bulimia, anorexia, hyperphagia and diabetes.

Beta-ketoamide compounds with MCH antagonistic activity

Compounds of formula I wherein the groups and residues A, B, b, X, Y, Z, R1, R2, R3, R5a and R5b have the meanings given in claim 1. The invention further relates to pharmaceutical compositions containing at least one amide according to the invention. As a result of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity, bulimia, anorexia, hyperphagia, and diabetes.

Substituted indolinones, preparation thereof and their use as pharmaceutical compositions

Indolinones of general formula I which are inhibitors of cell proliferation, particularly of tumour cells, and inhibitors of protein kinases. The following compounds are exemplary: (Z)-3-{1-[4-(N-(2-aminoethyl)-N-methylsulphonyl-amino)-phenylamino]-1-phenyl-methylidene}-5-phenylsulphonylamino-2-indolinone, (Z)-3-{1 -[4-(N-(2-dimethylaminoethyl)-N-phenylsulphonyl-amino)-phenylamino]-1-phenyl-methylidene}-5-phenylsulphonylamino-2-indolinone, and (Z)-3-{1-[4-(4-methylpiperazinomethyl)-phenylamino]-1-phenyl-methylidene}-5-phenylsulphonylamino-2-indolinone.

Substituted indolinones with kinase inhibitory activity

Substituted indolinones of general formula having effect on various kinases and cycline/CDK complexes and on the proliferation of various tumour cells. Exemplary compounds are: 3-Z-[1-(4-(N-Benzyl-N-methyl-aminomethyl)-phenylamino)-1-methyl-methylene]-5-a